Quantcast

Industry news that matters to you.  Learn more

Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker

Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

Sentinels in the Blood: a New Diagnostic for Pancreatic Cancer

Despite enormous research strides, detection methods for many diseases remain cumbersome and expensive, and often uncover illness only at advanced stages, when patient outcomes can be bleak. One such illness is pancreatic cancer, which may display no obvious symptoms in its early stages, yet can develop aggressively. Indeed, according to the American Cancer Society, a staggering 80 percent of those stricken with this form of cancer die within 1 year of diagnosis.

Immunovia Announces the Start of PANFAM-1, the Largest Ever Prospective Multi-center Clinical Study for Early Detection of Pancreatic Cancer

Immunovia AB today announced the start of PANFAM-1, a multicenter prospective validation study for the early diagnosis in familiar pancreatic cancer (FPC) high risk individuals. The first site now collecting blood samples is the Spanish research center Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study will run for three years across sites in both the US and Europe offering FPC screening programs.

Immunovia, OHSU Collaborating on Early Detection Test for Pancreatic Cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

Launch of Project Survival: Collaboration Aims to Uncover First Ever Biomarker for Pancreatic Cancer

The search to discover and validate the first-ever clinical biomarker to diagnose and treat pancreatic cancer is at the foundation of a new, cross-sector collaboration. Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach; the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC), a Harvard Medical School teaching hospital, and the Pancreatic Cancer Research Team (PCRT) managed by Cancer Research And Biostatistics (CRAB) announced today they will work together to eradicate the disease.